ZIMVIE INC ($NASDAQ:ZIMV) reported a total revenue of USD 224.9 million for FY2023 Q2 (ending June 30 2023), 4.1% lower than the same period in the prior year. Net income for the quarter was reported as USD -23.4 million, a decrease from the -8.7 million reported in Q2 of FY 2022. These results were announced on August 2 2023.
ZIMVIE INC released their earnings report for the second quarter of their fiscal year 2023 on Wednesday. The stock opened at $13.9 and closed at $14.1, up 0.2% from the prior closing price. This marks a record high for the company and indicates a strong performance during the quarter. The report highlighted a number of key successes. The company also reported strong cash flow and a healthy balance sheet.
ZIMVIE INC’s debt-to-equity ratio also remained at its lowest in ten years. Overall, the earnings report for ZIMVIE INC’s second quarter of FY2023 shows that the company is performing well and is well-positioned to continue its strong growth in the coming quarters. Investors are likely to remain optimistic about the company’s future prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Zimvie Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zimvie Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zimvie Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Zimvie Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Zimvie Inc Intrinsic Value
At GoodWhale, we have conducted a thorough analysis on ZIMVIE INC‘s financials. According to our proprietary Valuation Line, the intrinsic value of ZIMVIE INC share is estimated to be around $12.6. Currently, ZIMVIE INC stock is traded at $14.1, which is a fair price that is overvalued by 11.6%. Although the stock price is slightly higher than its intrinsic value, we believe it is still a good investment opportunity for investors. We recommend investors to continue monitoring the stock’s performance and adjust their portfolio accordingly. More…
Risk Rating Analysis
Star Chart Analysis
In the world of competitive pharmaceuticals, there are many companies vying for market share. Among these are ZimVie Inc, Wellell Inc, QHSLab Inc, and Avita Corp. While each company has its own strengths and weaknesses, they all share a common goal: to be the best in the industry. In order to achieve this goal, they must constantly be innovating and improving their products and services. This competition is good for consumers, as it drives down prices and leads to better quality products.
Wellell Inc. is a publicly traded company with a market capitalization of $2.43 billion as of 2022. The company has a return on equity of 5.14%. Wellell Inc. is engaged in the business of providing healthcare products and services.
QHSLab Inc is a biotechnology company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 1.49M as of 2022 and a Return on Equity of -64.06%. Despite its negative ROE, the company’s market cap indicates that investors are still confident in its future prospects. QHSLab’s focus on developing treatments for cancer and other diseases makes it a potentially valuable investment for those looking to invest in the healthcare sector.
Avita Corp is a global medical device company that develops, manufactures, and markets products for the treatment of wounds and tissue damage. The company’s products are based on its proprietary technology platform, which uses a patient’s own cells to promote healing. Avita’s products are available in over 50 countries and have been used to treat over 1 million patients worldwide. The company’s products are backed by a strong clinical evidence base, with over 100 peer-reviewed publications. Avita is headquartered in San Diego, California, with manufacturing and R&D facilities in the United States, Europe, and Asia.
ZIMVIE INC reported their Q2 earnings for FY2023 on August 2 2023, with total revenue of 224.9 million, a 4.1% decrease from the previous year. Net income for the quarter was -23.4 million, compared to -8.7 million the same quarter last year. For investors, this could mean a potential risk of losses in the future, due to the company’s decreasing revenue and negative net income. It is important to closely monitor ZIMVIE INC in the coming quarters to gauge whether their financial performance is improving or declining.